See more : SSLJ.com Limited (YGTYF) Income Statement Analysis – Financial Results
Complete financial analysis of Sera Prognostics, Inc. (SERA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sera Prognostics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Anhui Jiangnan Chemical Industry Co., Ltd. (002226.SZ) Income Statement Analysis – Financial Results
- Heron Therapeutics, Inc. (HRTX) Income Statement Analysis – Financial Results
- DBT SA (ALDBT.PA) Income Statement Analysis – Financial Results
- More Return Public Company Limited (MORE.BK) Income Statement Analysis – Financial Results
- A SPAC I Acquisition Corp. (ASCAR) Income Statement Analysis – Financial Results
Sera Prognostics, Inc. (SERA)
About Sera Prognostics, Inc.
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 306.00K | 268.00K | 82.00K | 25.00K | 36.00K |
| Cost of Revenue | 210.00K | 193.00K | 37.00K | 11.00K | 18.00K |
| Gross Profit | 96.00K | 75.00K | 45.00K | 14.00K | 18.00K |
| Gross Profit Ratio | 31.37% | 27.99% | 54.88% | 56.00% | 50.00% |
| Research & Development | 15.23M | 14.24M | 11.02M | 7.78M | 9.35M |
| General & Administrative | 16.34M | 16.78M | 14.09M | 6.56M | 4.28M |
| Selling & Marketing | 8.35M | 14.70M | 10.33M | 3.65M | 2.96M |
| SG&A | 24.69M | 31.48M | 24.42M | 10.20M | 7.24M |
| Other Expenses | 0.00 | 1.53M | 1.13M | -80.00K | -17.00K |
| Operating Expenses | 39.92M | 45.73M | 35.44M | 17.99M | 16.58M |
| Cost & Expenses | 40.13M | 45.92M | 35.48M | 18.00M | 16.60M |
| Interest Income | 1.64M | 456.00K | 145.00K | 42.00K | 64.00K |
| Interest Expense | 55.00K | 61.00K | 746.00K | 1.84M | 1.97M |
| Depreciation & Amortization | 900.00K | 1.22M | 659.00K | 895.00K | 946.00K |
| EBITDA | -35.29M | -42.91M | -33.60M | -17.11M | -13.60M |
| EBITDA Ratio | -11,531.70% | -16,464.55% | -41,784.15% | -68,456.00% | -37,786.11% |
| Operating Income | -39.82M | -45.65M | -35.40M | -17.97M | -16.56M |
| Operating Income Ratio | -13,013.40% | -17,034.33% | -43,164.63% | -71,884.00% | -45,997.22% |
| Total Other Income/Expenses | 3.58M | 1.47M | 386.00K | -1.88M | 55.00K |
| Income Before Tax | -36.24M | -44.19M | -35.01M | -19.85M | -16.52M |
| Income Before Tax Ratio | -11,843.79% | -16,487.31% | -42,693.90% | -79,392.00% | -45,891.67% |
| Income Tax Expense | 0.00 | 61.00K | 1.22M | 1.76M | 3.92M |
| Net Income | -36.24M | -44.25M | -36.23M | -21.61M | -20.44M |
| Net Income Ratio | -11,843.79% | -16,510.07% | -44,180.49% | -86,428.00% | -56,775.00% |
| EPS | -1.16 | -1.43 | -1.18 | -0.70 | -0.67 |
| EPS Diluted | -1.16 | -1.43 | -1.18 | -0.70 | -0.67 |
| Weighted Avg Shares Out | 31.20M | 30.94M | 30.77M | 30.70M | 30.70M |
| Weighted Avg Shares Out (Dil) | 31.20M | 30.94M | 30.77M | 30.70M | 30.70M |
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.34 per share a year ago.
SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
SALT LAKE CITY , Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for...
Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024
SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report...
Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial
Sera Prognostics Announces Publication of Positive AVERT PRETERM TRIAL Results in the International Peer-Reviewed Journal, Diagnostics SALT LAKE CITY , July 9, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by...
SERA PROGNOSTICS ADDED TO RUSSELL 2000 AND 3000 INDEXES FOLLOWING CONCLUSION OF 2024 INDEXES ANNUAL RECONSTITUTION
SALT LAKE CITY , July 1, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that as a result...
3 Stocks Under $10 With the Potential to Make You a Millionaire
Buying stocks that can make you millions is any investor's dream. That is why some investors consider micro-cap or small-cap stocks trading under $10.
SERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES
SALT LAKE CITY , May 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has been...
Sera Prognostics, Inc. (SERA) Q1 2024 Earnings Call Transcript
Sera Prognostics, Inc. (NASDAQ:SERA ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners Zhenya Lindgardt - President & Chief Executive Officer Austin Aerts - Chief Financial Officer Conference Call Participants...
SERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
SALT LAKE CITY , May 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the...
Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2024 Financial Results on May 8, 2024
SALT LAKE CITY , April 29, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report...
Source: https://incomestatements.info
Category: Stock Reports